Silo Pharma公司宣布,其用于治疗创伤后应激障碍的候选药物SPC-15取得了积极的稳定性研究数据。这一关键进展标志着该药物开发项目向前迈出了坚实一步,正稳步推进至首次人体临床试验阶段。稳定性数据的成功,为后续临床研究的顺利开展奠定了重要基础。
Silo Pharma公司宣布,其用于治疗创伤后应激障碍的候选药物SPC-15取得了积极的稳定性研究数据。这一关键进展标志着该药物开发项目向前迈出了坚实一步,正稳步推进至首次人体临床试验阶段。稳定性数据的成功,为后续临床研究的顺利开展奠定了重要基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.